Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07492927

Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer

Status
Recruiting
Phase
—
Study type
Observational
Enrollment
1,700 (estimated)
Sponsor
Xijing Hospital · Academic / Other
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.

Conditions

Timeline

Start date
2021-03-12
Primary completion
2026-12-31
Completion
2027-06-30
First posted
2026-03-25
Last updated
2026-03-25

Locations

10 sites across 2 countries: United States, China

Source: ClinicalTrials.gov record NCT07492927. Inclusion in this directory is not an endorsement.

Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer (NCT07492927) · Clinical Trials Directory